Quick Facts: Uses of Corinfar Retard

• High Blood Pressure: Employed in the management of high blood pressure (hypertension).
• Chest Pain: May be used to assist in the control of certain types of chronic, stable chest pain (angina).
• Vasospastic Angina: Can be utilized for the management of vasospastic angina.

---

Corinfar Retard, an extended-release formulation of nifedipine, is prescribed for the treatment of specific cardiovascular conditions. The primary therapeutic domains include the sustained management of high blood pressure, also known as hypertension. Maintaining blood pressure within a desired range may assist in reducing the workload on the heart and arteries.

Additionally, this medicine is indicated for the control of certain types of angina, or chest pain. This includes chronic stable angina, which may be associated with exertion, and vasospastic angina (Prinzmetal's or variant angina). For these applications, the medicine may help manage the frequency of anginal episodes. Corinfar Retard is a treatment option that must be used under the direction of a healthcare professional.

Corinfar Retard (nifedipine extended-release) is primarily prescribed for adults to manage chronic stable angina pectoris and high blood pressure (hypertension). In some cases, it may be used off-label for conditions like Raynaud's phenomenon or, under strict medical supervision, to manage certain hypertensive disorders during pregnancy.

However, this medication is not suitable for all patients. The use of Corinfar Retard is contraindicated in several situations to avoid serious health risks.

Contraindications and Caution

Condition	Status	Rationale/Note
Allergy	Cannot Use	Known hypersensitivity to nifedipine or other dihydropyridines.
Cardiogenic Shock	Cannot Use	Risk of profound hypotension and worsening cardiac function.
Unstable Angina	Cannot Use	Not for acute attacks; may worsen symptoms in some cases.
Recent Myocardial Infarction	Caution	Not recommended within 4 weeks of a heart attack.
Severe Aortic Stenosis	Caution	Risk of reducing coronary blood flow.
Severe Hypotension	Caution	May cause an excessive drop in blood pressure.
Severe Liver Impairment	Caution	Metabolism of the drug may be reduced, increasing drug levels.
Gastrointestinal Narrowing	Caution	Risk of tablet obstruction (bezoar formation) with extended-release forms.
Concomitant use with Rifampicin	Cannot Use	Rifampicin significantly reduces nifedipine's effectiveness.

Patients with heart failure should also be monitored closely, as calcium channel blockers are sometimes associated with worse outcomes in this population. Always discuss your full medical history and current medications with a healthcare professional before starting Corinfar Retard.

Interactions with other medicines and products

Corinfar Retard, which contains Nifedipine, interacts with several categories of medicinal products and substances, primarily due to effects on drug metabolism and additive blood pressure changes. All interaction information is based on official government regulatory documents.

Pharmacokinetic and Metabolic Interactions

Nifedipine is mainly metabolized by the CYP3A4 enzyme system. Co-administration with strong CYP3A4 Inhibitors, such as specific antifungals (e.g., Azole antimycotics) and antivirals (e.g., Anti-HIV Protease Inhibitors), is documented to increase Nifedipine plasma concentrations due to reduced clearance. Conversely, strong enzyme inducers, like the antitubercular medicine Rifampicin, are documented to significantly reduce Nifedipine plasma exposure, leading to a loss of therapeutic effect. Consequently, the combination of Corinfar Retard with Rifampicin is formally contraindicated.

Pharmacodynamic and Exposure Interactions

The co-administration of Nifedipine with Beta-blocking agents or other antihypertensive agents may result in an additive antihypertensive effect (risk of severe hypotension). Nifedipine is also documented to decrease the clearance of Digoxin, which can lead to increased plasma concentrations of Digoxin. Additionally, Nifedipine may alter the plasma levels of Quinidine.

Food, Herbal, and Special Caution

Ingestion of Grapefruit or Grapefruit Juice must be avoided while taking this medicine, as it is documented to increase Nifedipine plasma exposure. The herbal product St. John’s Wort is documented to reduce Nifedipine levels, and its co-administration is not recommended. Patients with Impaired Hepatic Function may exhibit prolonged Nifedipine clearance, resulting in increased systemic exposure.

Molecular Mechanism: Blocking L-type Calcium Channels

The core mechanism of Corinfar Retard (Nifedipine) is the highly specific antagonism of L-type Voltage-Gated Calcium Channels ( CaV1.2) located on the cell membranes of vascular smooth muscle cells (VSMCs). By binding to these channels, Nifedipine limits the influx of extracellular calcium ions ( Ca^2+). This molecular action interferes with the initiation of the muscle contraction sequence.

---

Physiological Cascade: Vasodilation and Afterload Reduction

The limitation of Ca^2+ influx interferes with the excitation-contraction coupling pathway, resulting in the relaxation and widening of the arteries (vasodilation). This widespread relaxation of peripheral and coronary arteries leads to a reduction in Systemic Vascular Resistance (SVR), which lowers the afterload—the mechanical stress the heart must overcome to eject blood. The Retard (sustained-release) formulation provides a sustained antagonism, a delivery profile associated with a dampened sympathetic counter-regulatory response compared to immediate-release formulations.

How to Use Corinfar Retard

Corinfar Retard is an extended-release pharmaceutical preparation used for long-term cardiovascular management. The medicine is taken exclusively via the oral route and is administered as a modified-release tablet. Adherence to the administration procedure is crucial to preserve the tablet's sustained-release properties, which are designed to provide consistent Nifedipine levels over a 24-hour period.

---

Official Administration Guidelines

Instruction Domain	Official Usage Pattern
Route and Form	The medicine is strictly for oral intake. The tablet is formulated for modified release and must be taken whole.
Dosing Schedule	Dosing generally begins at 30 mg or 60 mg taken once daily. Maintenance doses are typically 30 mg to 90 mg daily. Dose adjustments are made gradually, often in intervals of 7 to 14 days.
Frequency and Timing	The standard schedule requires the tablet to be taken once daily. It may be taken with or without food, but specific formulations may advise taking it on an empty stomach.
Procedural Requirements	The tablet must not be crushed, chewed, or divided under any circumstances, as this will destroy the extended-release mechanism. It should be swallowed with an adequate amount of liquid.

---

Use in Specific Populations

Dosing rules are adapted for certain patient groups. For individuals with hepatic impairment, caution is necessary, and a dose reduction may be required. Conversely, dose adjustment is generally not required for patients with renal impairment. The safety and efficacy of this medicine have not been established in the pediatric population (children under 18 years of age). Additionally, the official usage protocol includes a dietary restriction: products containing grapefruit or grapefruit juice must be avoided during the entire course of treatment.

Research Evidence / Overview of Studies for Corinfar Retard

Research Evidence for High Blood Pressure (Hypertension)

Research exploring the use of extended-release nifedipine in the context of hypertension, or high blood pressure, has been evaluated in adults using major study designs. This evidence base includes Randomized Controlled Trials (RCTs) and scientific papers that combine findings from multiple trials, known as meta-analyses. These studies examined whether the medicine was associated with changes in blood pressure readings, specifically monitoring shifts in systemic blood pressure metrics. Research also explored patterns related to the occurrence of major cardiovascular outcomes, such as nonfatal stroke, within the observed populations.

The findings from these analyses reported measurements related to changes in both the upper (systolic) and lower (diastolic) blood pressure metrics across various patient groups. Some of the data, including evidence of exposure duration, was documented via population-based studies that tracked exposure over periods exceeding a decade. While research provides context for blood pressure outcomes, the full scope of major cardiovascular outcomes over many years requires continued observation within the broader evidence landscape.

---

Research Evidence for Angina Pectoris

Extended-release nifedipine was studied in research exploring conditions characterized by episodic manifestations, such as stable angina pectoris (chest pain with exertion) and vasospastic angina (Prinzmetal's variant). The evidence available consists of controlled clinical trials and meta-analyses. These studies examined outcomes related to physical discomfort in the observed populations, with measurements capturing the frequency of reported anginal episodes and activity level, such as measured exercise tolerance.

Studies focusing on stable angina reported patterns related to changes in the frequency of episodes and measured exercise tolerance during the specific, defined time intervals of the study. Research in the context of vasospastic angina describes the patterns that were observed in outcomes related to the monitoring of coronary artery spasms.

Official documentation notes that evidence confirming patterns of sustained outcomes for anti-anginal use remains less complete when compared to the evidence available for treating high blood pressure. Study durations for evaluating symptom relief were often confined to shorter terms, which means data for long-term anti-anginal outcomes in the anti-anginal context remain insufficient.

Key Studies & References

1. Safety of Nifedipine in Patients With Hypertension: A Meta-Analysis of Published Randomized Controlled Trials
2. Antihypertensive Medications for Severe Hypertension in Pregnancy: A Systematic Review and Meta-Analysis

Common questions about Corinfar Retard (FAQ)

---

Q: Can I take Corinfar Retard with alcohol?

Official regulatory documents caution against using Corinfar Retard with alcohol. This combination is generally not recommended because it can increase the risk of certain adverse effects, such as enhanced drowsiness or other potential effects on the liver or central nervous system. Information regarding specific warnings can be found in the full product information.

---

Q: Does Corinfar Retard make you feel sleepy?

Studies and official information indicate that Corinfar Retard may be associated with somnolence, which is a medical term for drowsiness or sleepiness. This is noted as a possible side effect related to its effects on the central nervous system. If somnolence occurs, caution is generally advised when engaging in activities that require mental alertness.

---

Q: Can children under 12 years old take Corinfar Retard?

According to the official product information, the approved use, dosing, and indications for Corinfar Retard are established for patients 12 years of age and older. Its use in children under 12 years of age is not included or supported by the current regulatory labeling.

---

Q: How should I store Corinfar Retard?

Regulatory documents state that Corinfar Retard is intended to be kept at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). To maintain the medicine's quality, it is intended to be kept protected from both excessive moisture and direct light.

---

Q: What should I do if I miss a dose?

Official prescribing information includes specific instructions on how to handle a missed dose, based on timing. General instructions indicate that if it is near the time of the next scheduled dose, the missed dose is typically skipped, and the patient resumes the normal schedule. The labeling specifically cautions against taking two doses at once.

How to Store and Dispose of Corinfar Retard

The storage and disposal of Corinfar Retard (Nifedipine extended-release) must strictly follow official regulatory guidelines to maintain drug stability and ensure safety.

Storage Requirements

Condition	Detail
Temperature	Store at Controlled Room Temperature, between 15 C and 30 C.
Protection	Must be protected from light and protected from moisture.
Container Rule	Keep the medicine in its original container, tightly closed.
Child Safety	Keep this and all medication out of the reach of children.

Handling and Disposal

To maintain its integrity, the extended-release tablet must not be split, chewed, or crushed. For disposal, the preferred method is utilizing an official drug take-back program. If this option is unavailable, the product should be mixed with an unappealing substance, placed in a sealed bag, and disposed of in household trash to avoid environmental release.